More specifically, among these cases, 19 (48.7%) were associated with liraglutide, 9 (23.1%) with dulaglutide, 4 (10.3%) each with exenatide and semaglutide, while 1 (2.6%) case each was linked to lixisenatide, albiglutide, and tirzepatide
This product has been manufactured and prepared in the USA by a GMP certified facility in strict conformance with industry and governmental standards
The incidence numbers below show just how much phlebitis rates vary depending on the clinical setting, the catheter used, and the protocols in place
Elizabeth Rebello, an anesthesiologist at the University of Texas MD Anderson Cancer Center, was one of the committee members who voted against allowing the four peptides to be compounded, citing unknowns around safety and confusion for the public